TY - JOUR
T1 - Structure-activity relationship of ipglycermide binding to phosphoglycerate mutases
AU - Wiedmann, Mareike
AU - Dranchak, Patricia K
AU - Aitha, Mahesh
AU - Queme, Bryan
AU - Collmus, Christopher D
AU - Kashipathy, Maithri M
AU - Kanter, Liza
AU - Lamy, Laurence
AU - Rogers, Joseph M
AU - Tao, Dingyin
AU - Battaile, Kevin P
AU - Rai, Ganesha
AU - Lovell, Scott
AU - Suga, Hiroaki
AU - Inglese, James
N1 - Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Human phosphoglycerate mutase (dPGM) catalysis is dependent on a 2,3-bisphosphoglycerate cofactor, while the nonhomologous isozyme in many parasitic species is cofactor-independent (iPGM). This mechanistic and phylogenetic diversity offers an opportunity for selective pharmacologic targeting of glycolysis in disease-causing organisms. We previously discovered ipglycermide, a potent inhibitor of iPGM, from a large combinatorial cyclic peptide library. To fully delineate the ipglycermide pharmacophore, herein we construct a detailed structure-activity relationship using 280 substituted ipglycermide analogs. Binding affinities of these analogs to immobilized C. elegans iPGM, measured as fold-enrichment relative to the index residue by deep sequencing of an mRNA display library, illuminated the significance of each amino acid to the pharmacophore. Using co-crystal structures and binding kinetics, we show that the high affinity of ipglycermide for iPGM orthologs, from B. malayi, O. volvulus, D. immitis, and E. coli is achieved by a co-dependence between 1) the off-rate mediated by the macrocycle Cys14 thiolate coordination to an active-site Zn2+ ion in the iPGM phosphatase domain, and 2) shape-complementarity surrounding the macrocyclic core at the phosphotransferase-phosphatase domain interface. Our results show that the high affinity binding of ipglycermide to iPGMs freezes these structurally dynamic enzymes into an inactive, stable complex.
AB - Human phosphoglycerate mutase (dPGM) catalysis is dependent on a 2,3-bisphosphoglycerate cofactor, while the nonhomologous isozyme in many parasitic species is cofactor-independent (iPGM). This mechanistic and phylogenetic diversity offers an opportunity for selective pharmacologic targeting of glycolysis in disease-causing organisms. We previously discovered ipglycermide, a potent inhibitor of iPGM, from a large combinatorial cyclic peptide library. To fully delineate the ipglycermide pharmacophore, herein we construct a detailed structure-activity relationship using 280 substituted ipglycermide analogs. Binding affinities of these analogs to immobilized C. elegans iPGM, measured as fold-enrichment relative to the index residue by deep sequencing of an mRNA display library, illuminated the significance of each amino acid to the pharmacophore. Using co-crystal structures and binding kinetics, we show that the high affinity of ipglycermide for iPGM orthologs, from B. malayi, O. volvulus, D. immitis, and E. coli is achieved by a co-dependence between 1) the off-rate mediated by the macrocycle Cys14 thiolate coordination to an active-site Zn2+ ion in the iPGM phosphatase domain, and 2) shape-complementarity surrounding the macrocyclic core at the phosphotransferase-phosphatase domain interface. Our results show that the high affinity binding of ipglycermide to iPGMs freezes these structurally dynamic enzymes into an inactive, stable complex.
U2 - 10.1016/j.jbc.2021.100628
DO - 10.1016/j.jbc.2021.100628
M3 - Journal article
C2 - 33812994
VL - 296
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
SN - 0021-9258
M1 - 100628
ER -